首页 工具
登录
购物车
EZM 2302

EZM 2302

产品编号 T5605   CAS 1628830-21-6
别名: GSK3359088

EZM 2302 (GSK3359088) 是选择性口服精氨酸甲基转移酶 CARM1 抑制剂,IC50值为 6 nM。

TargetMol的所有产品和服务仅用于科学研究,不能被用于人体,我们也不向个人提供产品和服务。
EZM 2302 Chemical Structure
EZM 2302, CAS 1628830-21-6
规格 价格/CNY 货期 数量
1 mg ¥ 612 现货
2 mg ¥ 857 现货
5 mg ¥ 1,330 现货
10 mg ¥ 1,980 现货
25 mg ¥ 3,380 现货
50 mg ¥ 4,850 现货
100 mg ¥ 6,760 现货
500 mg ¥ 13,500 现货
1 mL * 10 mM (in DMSO) ¥ 1,730 现货
千万补贴 助力科研
BCA蛋白浓度测定试剂盒限时半价
Venetoclax限时半价
MG-132限时半价
产品目录号及名称: EZM 2302 (T5605)
点击图片重新获取验证码
选择批次  
纯度: 98%
纯度: 97.47%
更多批次查询请联系客服
生物活性
化学信息
存储 & 溶解度
参考文献
产品描述 EZM 2302 (GSK3359088) is a selective, and orally available arginine methyltransferase CARM1 inhibitor (IC50: 6 nM).
靶点活性 CARM1:6 nM
体外活性 EZM2302 (GSK3359088) is an inhibitor of CARM1 enzymatic activity in biochemical assays (IC50?=?6?nM) with broad selectivity against other histone methyltransferases. Ninety-six-hour EZM2302 treatment led to a concentration-dependent decrease in methylation of PABP1 (IC50?=?0.038?μM) and SmB (increased levels of SmBme0, EC50?=?0.018?μM), as well as in multiple aDMA bands (IC50?=?0.009?μM). Similar results were also observed in the NCI-H929 and U266B1 MM cell lines.
体内活性 Tumor growth inhibition studies were performed in SCID mice bearing subcutaneous RPMI-8226 xenografts with twice daily (BID) oral dosing on four dose groups: 37.5, 75, 150 and 300?mg per kilogram (mg/kg). EZM2302 showed dose-dependent exposure and tumor growth inhibition (TGI) after 21 days in the RPMI-8226 xenograft model. Tumors in all EZM2302 dose groups measured on day 21 showed significant decreases in tumor growth compared to vehicle. Tumor growth inhibition ranged from 45% in the 37.5?mg/kg dose group to 63% in the 300?mg/kg dose group.
激酶实验 CARM1 activity was measured as previously reported for the histone methyltransferases PRMT1/6/865 and PRMT558. Briefly, CARM1 was preincubated with compounds for 30?minutes at room temperature before reactions were initiated. Final assay conditions were 0.25?nM CARM1, 30?nM 3H-S-adenosyl-methionine (SAM), and 250?nM biotinylated peptide in buffer containing 20?mM bicine, 1?mM tris(2-carboxyethyl)phosphine, 0.005% bovine skin gelatin and 0.002% Tween-20, pH 7.5. The assays were quenched by the addition of 300?μM unlabeled SAM. The quantity of 3H-labeled peptide produced was measured by Flashplate.
细胞实验 Cultured cells in linear/log phase growth were split to a seeding density of 2e5 cells/mL in 2–20mLs of media, depending on the yield required at the end of the growth period. The compound was diluted in DMSO and added to each culture vessel with a final DMSO concentration of 0.2%. Cells were allowed to grow for 96?hours. At the conclusion of each treatment period, cells were harvested by centrifugation (5?minutes, 1200?rpm), and cell pellets were rinsed once with PBS before being frozen on dry ice pending further processing.
动物实验 For the in vivo efficacy studies, there were 8 mice per dose group and each mouse was inoculated subcutaneously at the right flank. All cells were suspended in a 0.2?mL mixture of base media and Matrigel at 1:1 for tumor development. RPMI-8226 cells were inoculated at 5?×?10^6 cells/mouse and treatment began when the mean tumor sizes reached 120?mm3 (28 days post-inoculation). CB-17 SCID Mice were assigned into groups using a randomized block design. EZM2302 or vehicle (0.5% methylcellulose in water) was administered orally BID at a dose volume of 37.5, 75, 150, or 300?mg/kg for 21 days. Body weights were measured twice a week for the duration of the study. Tumor size was measured twice weekly in two dimensions using a caliper, and the volume was expressed in cubic millimeters. Animals were euthanized 3?hours post-final dose, with blood and tissues collected for analysis.
别名 GSK3359088
分子量 585.09
分子式 C29H37ClN6O5
CAS No. 1628830-21-6

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度

DMSO: 100 mg/mL (170.91 mM)

溶液配制表

可选溶剂 浓度 体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.7091 mL 8.5457 mL 17.0914 mL 42.7285 mL
5 mM 0.3418 mL 1.7091 mL 3.4183 mL 8.5457 mL
10 mM 0.1709 mL 0.8546 mL 1.7091 mL 4.2728 mL
20 mM 0.0855 mL 0.4273 mL 0.8546 mL 2.1364 mL
50 mM 0.0342 mL 0.1709 mL 0.3418 mL 0.8546 mL
100 mM 0.0171 mL 0.0855 mL 0.1709 mL 0.4273 mL

TargetMol Calculator计算器

摩尔浓度计算器
稀释计算器
配液计算器
分子量计算器
=
X
X
X
=
X
=
/
g/mol

输入分子式,点击计算,可计算出产品的分子量。

TargetMol Library Books参考文献

1. Drew AE, et al. Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma. Sci Rep. 2017 Dec 21;7(1):17993.
Amodiaquine dihydrochloride dihydrate GSK3368715 EZH2-IN-15 SETDB1-TTD-IN-1 lutidinic acid PRMT5-IN-25 PRMT5-IN-2 AMI-1

相关化合物库

该产品包含在如下化合物库中:
抑制剂库 表观遗传库 组蛋白修饰化合物库 NO PAINS 化合物库 口服活性化合物库 已知活性化合物库 经典已知活性库 染色质修饰分子库

TargetMol Calculator剂量换算

对于不同动物的给药剂量换算,您也可以参考 更多...

TargetMol Calculator 体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。

第一步:请输入动物实验的基本信息
剂量
mg/kg
每只动物体重
g
给药体积
μL
动物数量
第二步:请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% ddH2O
计算 重置

技术支持

您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。

Keywords

EZM 2302 1628830-21-6 Chromatin/Epigenetic Histone Methyltransferase GSK 3359088 inhibit GSK3359088 Inhibitor GSK-3359088 EZM2302 EZM-2302 inhibitor

 

TargetMol Loading
陶术
生物
TargetMol®中国区唯一合作伙伴
点击进入陶术生物官网陶术生物
联系我们
400-820-0310

上海市静安区江场三路238号8楼